Athena Countouriotis

Chief Medical Officer, Ambit Biosciences.

Companies

BioMarin PharmaceuticalBoard member Dec 28, 2023 to now¹
Passage BIO, Inc.Board member Feb 27, 2020 to now²
Iovance BiotherapeuticsBoard member Jun 11, 2019 to now³
Turning Point Therapeutics, Inc.Board member Apr 16, 2019 to Aug 17, 2022⁴
Turning Point Therapeutics, Inc.Chief executive officer Apr 16, 2019 to Aug 17, 2022⁴
Turning Point Therapeutics, Inc.President Apr 16, 2019 to Aug 17, 2022⁴
Cardiff Oncology, Inc.Board member Sep 20, 2017 to Jun 24, 2019⁵
Avalanche BiotechnologiesSVP, Chief Medical Officer Jun 21, 2017 to Feb 20, 2018⁶
Halozyme TherapeuticsSVP and Chief Medical Officer Jan 5, 2015 to Feb 24, 2017⁷
Ambit BiosciencesChief Medical Officer May 15, 2013 to Nov 12, 2014⁸

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Jun 2, 2026Granted 7,490 shares of BioMarin Pharmaceutical⁹
May 20, 2025Granted 6,650 shares of BioMarin Pharmaceutical¹¹
May 21, 2024Granted 4,720 shares of BioMarin Pharmaceutical¹²
Dec 27, 2023Granted 2,180 shares of BioMarin Pharmaceutical¹³
Aug 17, 2022Returned to company 110,959 shares at $76.00 of Turning Point Therapeutics, Inc.¹⁰
Feb 9, 2022Granted 62,400 shares of Turning Point Therapeutics, Inc.¹⁴
Feb 9, 2022Sold 2,971 shares at $36.30 of Turning Point Therapeutics, Inc.¹⁴

The numbers on this page point here. Each one links to the record it came from.